Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab [Phase 3]
A Phase 3 trial comparing Bendamustine plus Rituximab vs CHOP plus Rituximab in various non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]
Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multipl…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating a cancer vaccine for previously untreated or relapsed Follicular Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]
Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2024-06-05Clinical Trial Update: IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial update on IBI376 in relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study status is comple…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]
A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of ibrutinib and venetoclax in relapsed or refractory follicular lymphoma has completed enrollmen…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 dose-finding and efficacy study of a triplet therapy (venetoclax, CC-486, and obinutuzumab) in follicular lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 clinical trial evaluating rituximab in patients with newly diagnosed stage II, stage III, or stage IV follicular lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma [Phase 2]
Phase 2 trial comparing obinutuzumab plus zanubrutinib versus obinutuzumab alone in relapsed/refractory follicular lymphoma; the study has c…
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating AMG 562 in relapsed/refractory DLBCL, MCL, or follicular lymphoma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden [Phase 2]
Phase 2 trial evaluating a chemotherapy-free combination of copanlisib (PI3K inhibitor) with obinutuzumab in previously untreated follicular…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies [Phase 1]
Phase 1 clinical trial update examining idelalisib after allogeneic HSCT in B-cell malignancies; the study is terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma [Phase 1, Phase 2]
Clinical trial of mocetinostat in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]
The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…
-
CLINICAL_TRIALS trial_result · 2024-01-22Clinical Trial Update: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma [Phase 3]
A Phase 3 trial comparing a proposed rituximab biosimilar (DRL_RI) to MabThera in follicular lymphoma has completed with results posted.